Avenciguat (BI 685509): sGC activator | CSPH
Phase 2
Therapeutic Area: Cardio-renal-metabolic Diseases
Indication: Clinically significant portal hypertension (CSPH)
This compound is under investigation, further information will be available soon.
Phase 2
Therapeutic Area: Cardio-renal-metabolic Diseases
Indication: Clinically significant portal hypertension (CSPH)
This compound is under investigation, further information will be available soon.